Literature DB >> 29122700

Using reference values to define disease based on the lower limit of normal biased the population attributable fraction, but not the population excess risk: the example of chronic airflow obstruction.

Peter Burney1, Cosetta Minelli2.   

Abstract

BACKGROUND: The impact of disease on population health is most commonly estimated by the population attributable fraction (PAF), or less commonly by the excess risk, an alternative measure that estimates the absolute risk of disease in the population that can be ascribed to the exposure. Using chronic airflow obstruction as an example, we examined the impact on these estimates of defining disease based on different "normal" values.
METHOD: We estimated PAF and the excess risk in scenarios in which the true rate of disease was 10% in the exposed and 5% in the unexposed, and where either 50% or 20% of the population was exposed. Disease definition was based on a "lower limit of normal", using the 5th, 1st and 0.2nd centile of values in a "normal" population as thresholds to define normality.
RESULTS: Where normality is defined by centiles of values in a "normal" population, PAF is strongly influenced by which centile is selected to define normality. This is not true for the population excess risk.
CONCLUSION: Care should be taken when interpreting estimates of PAF when disease is defined from a centile of a normal population.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lower limit of normal; Normal values; Population attributable fraction; Population excess risk; Reference values; Respiratory function

Mesh:

Year:  2017        PMID: 29122700     DOI: 10.1016/j.jclinepi.2017.10.020

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  1 in total

1.  Lung function: what constitutes (ab)normality?

Authors:  José Alberto Neder; Danilo Cortozi Berton; Denis E O'Donnell
Journal:  J Bras Pneumol       Date:  2022-05-30       Impact factor: 2.800

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.